Pharmaceutically Acceptable Salt and Crystal Form of Tetrahydronaphthalene Derivative
Summary
USPTO published patent application US20260098027A1 for a pharmaceutically acceptable salt and crystal form of a tetrahydronaphthalene derivative, specifically covering (S)-3-(5-(4-((1-(4-((1R,2R)-6-hydroxy-2-isobutyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and its preparation method. Inventors include Lina Jia, Junran Yang, Zhenxing Du, Lin Wang, Qiyun Shao, and Jun Feng.
What changed
USPTO published patent application US20260098027A1 covering a new pharmaceutical salt and crystal form of a tetrahydronaphthalene derivative compound. The application discloses the salt form's improved stability for clinical treatment applications and includes detailed preparation methods. The compound is classified under CPC codes C07D 401/14 and A61K 31/496 with potential oncology indication (A61P 35/00).
Pharmaceutical companies developing similar compounds or anti-cancer agents should review this publication for potential freedom-to-operate concerns. Competitors may need to design around these claims or assess licensing opportunities. Research institutions may find the preparation methods useful for related drug development.
What to do next
- Monitor for patent grant status
- Review claims for competitive landscape
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTAL FORM OF TETRAHYDRONAPHTHALENE DERIVATIVE, AND PREPARATION METHOD
Application US20260098027A1 Kind: A1 Apr 09, 2026
Inventors
Lina Jia, Junran YANG, Zhenxing DU, Lin WANG, Qiyun SHAO, Jun FENG
Abstract
The present invention relates to a pharmaceutically acceptable salt and a crystal form of a tetrahydronaphthalene derivative, and a preparation method. Specifically, the present disclosure provides a pharmaceutically acceptable salt and a crystal form of (S)-3-(5-(4-((1-(4-((1R,2R)-6-hydroxy-2-isobutyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine- 2,6-dione, and a preparation method therefor. The corresponding salt has good stability and can be better used for clinical treatment.
CPC Classifications
C07D 401/14 A61K 31/496 A61P 35/00
Filing Date
2023-09-28
Application No.
19112795
Related changes
Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.